Chlorambucil
- Generic Name
- Chlorambucil
- Brand Names
- Leukeran
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19Cl2NO2
- CAS Number
- 305-03-3
- Unique Ingredient Identifier
- 18D0SL7309
- Background
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
- Indication
For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Hodgkins Disease (HD), Indolent Lymphoma, Lymphoma, Lymphoma, Diffuse, MALT Lymphoma, Mantle Cell Lymphoma (MCL), Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Waldenström's Macroglobulinemia (WM), Giant follicular lymphoma
- Associated Therapies
- -
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT06319456
- Locations
- 🇨🇳
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 218
- Registration Number
- NCT04578613
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 155
- Registration Number
- NCT04075292
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 211
- Registration Number
- NCT03462719
- Locations
- 🇨🇦
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02915224
- Locations
- 🇬🇷
Attiko Hospital; Haematology Clinic, Athens, Greece
🇬🇷General Hospital G. Papanikolaou; Hematology, BMT Unit, Thessaloniki, Greece
🇬🇷AXEPA Pathology Section; A Pathology Clinic, Thessaloniki, Greece
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 603
- Registration Number
- NCT02612311
- Locations
- 🇬🇧
TG Therapeutics Investigational Trial Site, Wolverhampton, United Kingdom
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
- Conditions
- Interventions
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 535
- Registration Number
- NCT02475681
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
- Conditions
- Interventions
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT02336048
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain
🇪🇸Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain
🇮🇹Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Sant'Andrea Delle Fratte (PG), Umbria, Italy
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 229
- Registration Number
- NCT02264574
- Locations
- 🇬🇧
Site Reference ID/Investigator# 0867, Harlow, Essex, United Kingdom
🇦🇺Site Reference ID/Investigator# 0888, Ballarat, Victoria, Australia
🇦🇹Site Reference ID/Investigator# 0869, Salzburg, Austria
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 445
- Registration Number
- NCT02242942
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇮🇹Az. Osp. S. Maria; Dept. Di Oncologia Medica, Terni, Umbria, Italy
🇦🇹Wilhelminenspital; I. Medizinische Abt., Wien, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.